David Pacitti Acquires Shares in Orchestra BioMed Holdings
David Pacitti bought 17,327 shares of Orchestra BioMed on June 23, 2026.
Key Points
- David Pacitti purchased 17,327 shares of Orchestra BioMed Holdings on June 23, 2026, with the stock trading near $3.98.
- Orchestra BioMed has a market cap of about $234 million and a 52-week range between $2.20 and $5.42.
- Analysts maintain a positive outlook with several buy ratings and price targets as high as $20.00.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
David Pacitti recently bought 17,327 shares of Orchestra BioMed Holdings, Inc. (NasdaqGM: OBIO) on June 23, 2026. The shares were trading near $3.98 on Friday, reflecting his investment in the healthcare company.
Insider Buying and Selling at Orchestra BioMed Holdings, Inc.
On June 23, 2026, David Pacitti acquired 17,327 shares of Orchestra BioMed. This transaction was not under a Rule 10b5-1 plan. Other insiders, such as Eric Fain and Jason Aryeh, also made significant transactions around the same date, with Fain buying 17,327 shares and Aryeh purchasing 42,553 shares.
Other Institutional Activity in Orchestra BioMed Holdings
RTW Investments, LP maintained its position with 8,306,063 shares valued at approximately $35.3 million. Perceptive Advisors LLC trimmed its holdings by 89,350 shares, leaving it with 5,037,906 shares worth about $21.4 million, a 1.7% decrease. Vanguard Capital Management LLC opened a new position with 2,204,319 shares valued at around $9.4 million. Propel Bio Management, LLC also initiated a new position, acquiring 896,701 shares worth about $3.8 million. Millennium Management LLC significantly increased its stake by 459,070 shares, a 188.6% rise, to hold a total of 702,543 shares valued at roughly $3.0 million.
Orchestra BioMed Holdings, Inc. Stock Down 24.8%
Shares of NasdaqGM:OBIO traded near $3.98 on Friday. Orchestra BioMed Holdings, Inc. has a market cap of approximately $234 million. The stock has a 52-week low of $2.20 and a high of $5.42, with a 50-day moving average of $4.03 and a 200-day moving average of $3.99. The company has a current ratio of 7.03 and a quick ratio of 6.90, with a debt-to-equity ratio of 31.10.
$OBIO stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
In its latest earnings report, Orchestra BioMed Holdings posted revenue of $32.7 million, though it experienced a revenue decline of 87.3%. The company recorded a net margin of -166.96% and a return on equity of -161.12%. The next earnings report is expected on May 12, 2026.
Analysts Set New Price Targets
On May 19, 2026, B. Riley Securities maintained its buy rating for Orchestra BioMed with a $10.00 price target. HC Wainwright & Co. reiterated its buy rating with the same target on May 14. Barclays maintained a buy rating with a $13.00 target on May 13. The consensus among six analysts is a buy rating, with a mean price target of $12.17.
About Orchestra BioMed Holdings, Inc.
Orchestra BioMed Holdings, Inc. is a healthcare company based in New Hope, Pennsylvania. It focuses on developing bioelectronic therapies and medical devices. Its main products include the Atrioventricular Interval Modulation therapy to lower blood pressure and the Virtue Sirolimus AngioInfusion Balloon for treating artery disease. The company collaborates with Medtronic and Terumo for various product developments.
Bottom Line
David Pacitti's recent purchase of Orchestra BioMed Holdings shares signals insider interest in the company's future. The stock's market performance and institutional activities, along with analyst buy ratings, reflect a cautious optimism. However, as always, it's important to remember that insider transactions are just one piece of the investment puzzle.
Get Orchestra BioMed Holdings, Inc. alerts
New 13F filings, insider trades, and analyst moves on $OBIO, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.